Previous 10 | Next 10 |
Gainers: Cullinan Oncology (CGEM) +21%. Concert Pharmaceuticals (CNCE) +20%. Babylon Holdings BBLN +16%. Blue Water Vaccines (BWV) +14%. ViewRay (VRAY) +10%. Losers: Eargo (EAR) -24%. Senseonics (SENS) -14%. Ascendis Pharma (ASND) -11%. Evaxion Biotech...
Dutch Bros (BROS) -39% on Q1 earnings release. Eargo (EAR) -24%. Beyond Meat (BYND) -28% on Q1 earnings release. Evaxion Biotech (EVAX) -17% on Q1 earnings release. Senseonics Holdings (SENS) -12%. ironSource (IS) -11% on Q1 earnings rele...
Evaxion Biotech A/S (EVAX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Corey Davis – LifeSci Advisors Lars Wegner – Chief Executive Officer Jesper Nyegaard Nissen – Interim Chief Financial Officer Conference Call Participants Kevin DeGeet...
Evaxion Biotech ADS press release (EVAX): Q1 GAAP EPS of -$0.25 beats by $0.08. As of March 31, 2022, cash and cash equivalents were $31.4 million as compared to $32.2 million as of December 31, 2021. Guidance: We expect our existing cash and cash equivalents will be sufficient to f...
Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanoma Completed recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving first dose Announced publication on personalized therapy with EVX-01 in...
Gainers: Biohaven Pharmaceutical (BHVN) +71%. AdaptHealth (AHCO) +31%. Evaxion Biotech (EVAX) +25%. Assertio (ASRT) +22%. Haemonetics (HAE) +16%. Losers: Bausch Health (BHC) -26%. GoodRx (GDRX) -24%. Akanda (AKAN) -21%. Novavax ...
Are you searching for good penny stocks to buy? In May 2022, that is more easily said than done. With the stock market down at the start of the week, sentiment is cautious ahead of Wednesday’s CPI data. In what is expected to be one of the most important economic reports of the y...
Biohaven Pharmaceutical BHVN +72% on Q1 results. Evaxion Biotech (EVAX) +54% announces successful production of personalized cancer immunotherapies in phase 1/2a clinical trial for EVX-02. Vroom VRM +36% on Q1 results. Vertex Energy VTNR +16% on Q1 results. ...
Evaxion Biotech A/S (EVAX) said on Tuesday that it completed the production of all batches of personalized cancer immunotherapies for its Phase 1/2a clinical trial for EVX-02 in adjuvant melanoma. Evaxion (EVAX) ADRs added ~46% in the pre-market after the announcement. EVX-02 progra...
COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has suc...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...